Ratings Nu Skin Enterprises, Inc. Deutsche Boerse AG

Equities

NUS

US67018T1051

Market Closed - Deutsche Boerse AG 11:33:25 28/06/2024 am IST 5-day change 1st Jan Change
10 EUR +2.04% Intraday chart for Nu Skin Enterprises, Inc. -11.50% -42.53%

Summary

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The company's profit outlook over the next few years is a strong asset.
  • The company's attractive earnings multiples are brought to light by a P/E ratio at 11.58 for the current year.
  • The company shows low valuation levels, with an enterprise value at 0.4 times its sales.
  • The company has a low valuation given the cash flows generated by its activity.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company sustains low margins.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Sector: Personal Products

1st Jan change Capi. Investor Rating ESG Refinitiv
-42.53% 523M -
+14.34% 137B
B-
+21.74% 79.62B
A+
-6.17% 69.77B
A-
-27.25% 38.15B
B+
-15.56% 34.81B -
+0.63% 32.75B
B-
+8.56% 17.97B
A-
+22.11% 16.88B
B
+8.75% 12.77B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NUS Stock
  4. NUS Stock
  5. Ratings Nu Skin Enterprises, Inc.